Santafe News Online

DelveInsight’s “Complicated Urinary Tract Infection Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Complicated Urinary Tract Infection, historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Complicated Urinary Tract Infection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Complicated Urinary Tract Infection Market Forecast

Some of the key facts of the Complicated Urinary Tract Infection Market Report:

• The Complicated Urinary Tract Infections market size across the 7MM was valued at around USD 1,375 million in 2025 and is expected to expand at a CAGR of 5.7%, reaching approximately USD 2,259 million by 2034 in major markets including the US, EU4, the UK, and Japan.

• In March 2025, Meiji Seika Pharma announced that it had achieved positive results in a global Phase III clinical trial of OP0595, a novel ß-lactamase inhibitor developed to combat AMR. The trial targeted patients with cUTI or acute, uncomplicated pyelonephritis.

• In January 2025, Wockhardt announced that ZAYNICH demonstrated unprecedented efficacy in a global, pivotal Phase III study for cUTI, achieving a clinical cure rate of 96.8% and successfully meeting superiority criteria for registration.

• In 2024, in the EU4 and the UK, Germany has the highest market size of approximately USD 115 million.

• In 2024, the total market size for cUTI in Japan was approximately 120 USD million.

• In 2024, the Complicated Urinary Tract Infection Diagnosed Incident Cases were approximately 3,558,000 in the US.

• In 2024, the age-specific cases of cUTI were approximately 40,000, 268,000, 247,000, 511,500, 1,759,500 and 732,000 cases for 0-17 years, 18–44 years, 45–54 years, 55–64 years, 65–84 years and =85 years, respectively, in the US.

• In the US, male accounted for approximately 30% cases and female accounted for ~70% cases of cUTI in 2024.

• In 2024, the treated Cases of cUTI was approximately 10,746,500 in the 7MM, out of which ~ 8,266,500 were 1st line and ~ 2,480,000 were recurrent rate.

• Key Complicated Urinary Tract Infection Companies: Allecra Therapeutics, Merck Sharp & Dohme, AbbVie, Shionogi, Melinta Therapeutics, Spero Therapeutics, Wockhardt, Meiji, Venatorx Pharmaceuticals, Evopoint Pharmaceuticals, and others

• Key Complicated Urinary Tract Infection Therapies: EXBLIFEP (Cefepime/Enmetazobactam), RECARBRIO (imipenem, cilastatin, and relebactam), AVYCAZ/ ZAVICEFTA (Ceftazidime – Avibactam), FETROJA (cefiderocol), VABOMERE (Meropenem/vaborbactam), Tebipenem PIntravenousoxil Hydrobromide, Cefepime-zidebactam, Cefepime/ taniborbactam, Nacubactam (OP0595), XNW4107, and others

• The Complicated Urinary Tract Infection market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Complicated Urinary Tract Infection pipeline products will significantly revolutionize the Complicated Urinary Tract Infection market dynamics.

Complicated Urinary Tract Infection Overview

Complicated Urinary Tract Infection (UTIs) are infections that can occur anywhere in the urinary tract, which includes the kidneys, ureters, bladder, and urethra. However, they most commonly affect the lower urinary tract, which includes the bladder and the urethra.

Get a Free sample for the Complicated Urinary Tract Infection Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market

Complicated Urinary Tract Infection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Complicated Urinary Tract Infection Epidemiology Segmentation:

The Complicated Urinary Tract Infection market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Complicated Urinary Tract Infection

• Prevalent Cases of Complicated Urinary Tract Infection by severity

• Gender-specific Prevalence of Complicated Urinary Tract Infection

• Diagnosed Cases of Episodic and Chronic Complicated Urinary Tract Infection

Download the report to understand which factors are driving Complicated Urinary Tract Infection epidemiology trends @ Complicated Urinary Tract Infection Epidemiology Forecast

Complicated Urinary Tract Infection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Complicated Urinary Tract Infection market or expected to get launched during the study period. The analysis covers Complicated Urinary Tract Infection market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Complicated Urinary Tract Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Complicated Urinary Tract Infection Therapies and Key Companies

• EXBLIFEP (Cefepime/Enmetazobactam): Allecra Therapeutics

• RECARBRIO (imipenem, cilastatin, and relebactam): Merck Sharp & Dohme

• AVYCAZ/ ZAVICEFTA (Ceftazidime – Avibactam): AbbVie

• FETROJA (cefiderocol): Shionogi

• VABOMERE (Meropenem/vaborbactam): Melinta Therapeutics

• Tebipenem PIntravenousoxil Hydrobromide: Spero Therapeutics

• Cefepime-zidebactam: Wockhardt

• Cefepime/ taniborbactam:Venatorx Pharmaceuticals

• Nacubactam (OP0595): Meiji

• XNW4107: Evopoint Pharmaceuticals

Discover more about therapies set to grab major Complicated Urinary Tract Infection market share @ Complicated Urinary Tract Infection Treatment Landscape

Complicated Urinary Tract Infection Market Drivers

• Rising use of urinary catheters and other drainage devices is likely to offer an uptick in cUTI treatment market growth as patients using urinary catheters are more likely to acquire cUTI.

• Rising demand for antibiotics since antibiotics are the only treatment for cUTI and UTIs.

Complicated Urinary Tract Infection Market Barriers

• Currently, there is a lack high pitency approved antibiotic drug for oral use, so first-ever FDA approval for oral drugs will provide a first-mover advantage.

• Increase in the number of mergers/acquisitions and collaborations among companies to develop safe and effective drugs will accelerate the market growth.

Scope of the Complicated Urinary Tract Infection Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Complicated Urinary Tract Infection Companies: Allecra Therapeutics, Merck Sharp & Dohme, AbbVie, Shionogi, Melinta Therapeutics, Spero Therapeutics, Wockhardt, Meiji, Venatorx Pharmaceuticals, Evopoint Pharmaceuticals, and others

• Key Complicated Urinary Tract Infection Therapies: EXBLIFEP (Cefepime/Enmetazobactam), RECARBRIO (imipenem, cilastatin, and relebactam), AVYCAZ/ ZAVICEFTA (Ceftazidime – Avibactam), FETROJA (cefiderocol), VABOMERE (Meropenem/vaborbactam), Tebipenem PIntravenousoxil Hydrobromide, Cefepime-zidebactam, Cefepime/ taniborbactam, Nacubactam (OP0595), XNW4107, and others

• Complicated Urinary Tract Infection Therapeutic Assessment: Complicated Urinary Tract Infection current marketed and Complicated Urinary Tract Infection emerging therapies

• Complicated Urinary Tract Infection Market Dynamics: Complicated Urinary Tract Infection market drivers and Complicated Urinary Tract Infection market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Complicated Urinary Tract Infection Unmet Needs, KOL’s views, Analyst’s views, Complicated Urinary Tract Infection Market Access and Reimbursement

To know more about Complicated Urinary Tract Infection companies working in the treatment market, visit @ Complicated Urinary Tract Infection Clinical Trials and Therapeutic Assessment

Table of Contents

1. Complicated Urinary Tract Infection Market Report Introduction

2. Executive Summary for Complicated Urinary Tract Infection

3. SWOT analysis of Complicated Urinary Tract Infection

4. Complicated Urinary Tract Infection Patient Share (%) Overview at a Glance

5. Complicated Urinary Tract Infection Market Overview at a Glance

6. Complicated Urinary Tract Infection Disease Background and Overview

7. Complicated Urinary Tract Infection Epidemiology and Patient Population

8. Country-Specific Patient Population of Complicated Urinary Tract Infection

9. Complicated Urinary Tract Infection Current Treatment and Medical Practices

10. Complicated Urinary Tract Infection Unmet Needs

11. Complicated Urinary Tract Infection Emerging Therapies

12. Complicated Urinary Tract Infection Market Outlook

13. Country-Wise Complicated Urinary Tract Infection Market Analysis (2020–2034)

14. Complicated Urinary Tract Infection Market Access and Reimbursement of Therapies

15. Complicated Urinary Tract Infection Market Drivers

16. Complicated Urinary Tract Infection Market Barriers

17. Complicated Urinary Tract Infection Appendix

18. Complicated Urinary Tract Infection Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/